)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Sight Sciences
Sight Sciences (SGHT) investor relations material
Sight Sciences Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary4 Nov, 2026
Executive summary
Record Q3 revenue of $24.9M, up 25.2% YoY, with record Interventional Dry Eye revenue and continued Interventional Glaucoma growth.
Net loss narrowed to $6.8M from $8.2M; FY26 revenue guidance was raised to $92M-$93M.
Products have been used in over 500,000 procedures; strategy emphasizes earlier procedure-based care and shared glaucoma and dry eye practices and patients.
Financial highlights
Q3 gross profit rose 24.6% to $21.4M; gross margin was 85.9% versus 86.4% a year earlier.
Operating expenses rose 10% to $27.5M; adjusted OpEx was $24.0M, up 21%. SG&A rose to $24.8M, while R&D fell to $2.7M.
Q3 net loss was $6.8M versus $8.2M; diluted loss per share was $0.12 versus $0.16.
9M revenue increased 19.4% to $68.0M; net loss narrowed to $24.2M from $34.3M.
Outlook and guidance
FY26 revenue guidance raised to $92M-$93M from $88M-$92M, implying 19%-20% YoY growth; adjusted OpEx guidance maintained at $92M-$94M, up 5%-7%.
FY26 Interventional Dry Eye revenue outlook raised to ~$12M from $9M-$11M; Interventional Glaucoma outlook is $80M-$81M.
Management expects Interventional Glaucoma momentum to continue into Q4 and 2027; OMNI Ultra is expected to support growth. No 2027 guidance was given.
Near-term Interventional Dry Eye priorities include scaling within First Coast and Novitas, growing accounts and utilization, and pursuing broader payer access; decision timing remains uncertain.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Sight Sciences
- Q3 growth and FY26 guidance support expansion across TearCare and OMNI.SGHT
Investor presentation - Strong growth in glaucoma and dry eye platforms, with new products and expanded market access ahead.SGHTMorgan Stanley 24th Annual Global Healthcare Conference
- Interventional glaucoma and dry eye platforms drive growth, clinical impact, and market expansion.SGHTInvestor presentation
- Q2 2026 revenue up 20% YoY, gross margin 91%, net loss narrowed, and guidance raised.SGHTQ2 2026
- Omni and TearCare outperform amid regulatory shifts, with major growth expected as coverage expands.SGHTStifel 2025 Virtual Ophthalmology Forum
- Directors and auditor were re-elected and ratified, with no questions from stockholders.SGHTAGM 2026
- OMNI and TearCare drive growth with innovation, higher utilization, and expanding market access.SGHTStifel 2026 Virtual Ophthalmology Forum
- Q4 revenue grew 7% with strong margins; 2026 guidance projects up to 14% growth.SGHTQ4 2025
- Q1 2025 revenue fell 9% to $17.5M; guidance reaffirmed despite tariff and policy headwinds.SGHTQ1 2025
Next Sight Sciences earnings date
Stifel 2026 Healthcare Conference 202611 Nov, 2026
Sight Sciences
Next Sight Sciences earnings date
Stifel 2026 Healthcare Conference 202611 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Sight Sciences, Inc. is a medical technology company focused on developing and commercializing treatments for eye diseases. The company's main business is centered around creating devices that address conditions affecting the eye, particularly in the areas of glaucoma and dry eye disease. Sight Sciences' products are designed to improve patient outcomes by offering minimally invasive solutions that target the underlying causes of these conditions. It serves the ophthalmology and optometry sectors, providing tools for healthcare professionals to enhance the treatment of common but serious eye health issues. The company is headquartered in Menlo Park, California, and its shares are listed on the NASDAQ.